PGL
MCID: PRS123
MIFTS: 39

Persistent Generalized Lymphadenopathy (PGL)

Categories: Immune diseases

Aliases & Classifications for Persistent Generalized Lymphadenopathy

MalaCards integrated aliases for Persistent Generalized Lymphadenopathy:

Name: Persistent Generalized Lymphadenopathy 12 15
Persistant Generalized Lymphadenopathy 73
Pgl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060314
UMLS 73 C0856916

Summaries for Persistent Generalized Lymphadenopathy

Disease Ontology : 12 A lymph node disease characterized by enlarged, non-painful lymph nodes occurring for more than three to six months for which no other reason can be found.

MalaCards based summary : Persistent Generalized Lymphadenopathy, also known as persistant generalized lymphadenopathy, is related to paragangliomas 1 and hereditary paraganglioma-pheochromocytoma syndromes. An important gene associated with Persistent Generalized Lymphadenopathy is SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B), and among its related pathways/superpathways are Carbon metabolism and Pyruvate metabolism and Citric Acid (TCA) cycle. The drugs Lamivudine and Emtricitabine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, skin and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 76 Persistent generalized lymphadenopathy (PGL) is enlarged painful lymph nodes occurring in a couple of... more...

Related Diseases for Persistent Generalized Lymphadenopathy

Diseases related to Persistent Generalized Lymphadenopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 paragangliomas 1 32.9 SDHB SDHC SDHD
2 hereditary paraganglioma-pheochromocytoma syndromes 31.6 SDHA SDHAF2 SDHB SDHC SDHD TMEM127
3 paraganglioma 29.7 SDHA SDHAF2 SDHB SDHC SDHD TMEM127
4 pheochromocytoma 29.3 EPAS1 SDHA SDHAF2 SDHB SDHC SDHD
5 6-phosphogluconolactonase deficiency 11.4
6 c1q nephropathy 10.2 CD40LG CD79A
7 immunoglobulin g deficiency 10.2 CD40LG CD79A
8 cryofibrinogenemia 10.2 CD40LG CD79A
9 heparin-induced thrombocytopenia 10.2 CD40LG CD79A
10 immunoglobulin a deficiency 1 10.2 CD40LG CD79A
11 sporotrichosis 10.2 CD40LG CD79A
12 congenital syphilis 10.2 CD40LG CD79A
13 syphilis 10.2 CD40LG CD79A
14 secondary syphilis 10.2 CD40LG CD79A
15 immunodeficiency-centromeric instability-facial anomalies syndrome 1 10.2 CD40LG CD79A
16 ocular toxoplasmosis 10.2 CD40LG CD79A
17 toxoplasmosis 10.2 CD40LG CD79A
18 immunodeficiency with hyper-igm, type 1 10.2 CD40LG CD79A
19 congenital toxoplasmosis 10.2 CD40LG CD79A
20 immunoglobulin alpha deficiency 10.2 CD40LG CD79A
21 cryptosporidiosis 10.2 CD40LG CD79A
22 pustulosis palmaris et plantaris 10.2 CD40LG CD79A
23 dysgerminoma of ovary 10.1 CD40LG CD79A
24 glomus tumor 10.1 SDHB SDHD
25 marginal zone b-cell lymphoma 10.1 CD40LG CD79A
26 meningoencephalitis 10.1 CD40LG CD79A
27 indeterminate leprosy 10.1
28 cryoglobulinemia 10.1 CD40LG CD79A
29 multiple endocrine neoplasia, type iia 10.1 SDHB SDHD
30 lymphoma 10.1
31 multiple endocrine neoplasia 10.1 SDHB SDHC
32 agammaglobulinemia, x-linked 10.1 CD40LG CD79A
33 immune deficiency disease 10.1 CD40LG CD79A
34 seminal vesicle tumor 10.1 SDHA SDHB
35 lymphosarcoma 10.0
36 spastic quadriplegia 10.0 SDHA SDHD
37 quadriplegia 10.0 SDHA SDHD
38 chondroma 10.0 SDHB SDHC SDHD
39 paraganglioma and gastric stromal sarcoma 10.0 SDHB SDHC SDHD
40 iga glomerulonephritis 10.0 CD40LG CD79A
41 neurofibromatosis, type iv, of riccardi 10.0 SDHB SDHC SDHD
42 von hippel-lindau syndrome 10.0 SDHB SDHC SDHD
43 cowden disease 10.0 SDHB SDHC SDHD
44 renal cell carcinoma, nonpapillary 10.0
45 leprosy 3 10.0
46 glioma 10.0
47 hansen's disease 10.0
48 acquired immunodeficiency syndrome 9.9
49 lymphatic system disease 9.9 SDHB SDHC SDHD TMEM127
50 extra-adrenal pheochromocytoma 9.8 SDHAF2 SDHB SDHC SDHD

Graphical network of the top 20 diseases related to Persistent Generalized Lymphadenopathy:



Diseases related to Persistent Generalized Lymphadenopathy

Symptoms & Phenotypes for Persistent Generalized Lymphadenopathy

MGI Mouse Phenotypes related to Persistent Generalized Lymphadenopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.5 CD40LG CD79A EPAS1 SDHB SDHC SDHD
2 homeostasis/metabolism MP:0005376 9.23 CD40LG CD79A EPAS1 SDHA SDHB SDHC

Drugs & Therapeutics for Persistent Generalized Lymphadenopathy

Drugs for Persistent Generalized Lymphadenopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
2
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2 143491-57-0 60877
3
Darunavir Approved Phase 4,Phase 3,Phase 2 206361-99-1, 635728-49-3 213039
4
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
5
Tenofovir Experimental, Investigational Phase 4,Phase 3,Phase 2 147127-20-6 464205
6 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
7 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9
protease inhibitors Phase 4,Phase 3,Phase 2
10 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
11 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
17
Abacavir Approved, Investigational Phase 3,Phase 2 136470-78-5 65140 441300
18 Dolutegravir Approved Phase 3,Phase 2 1051375-16-6 54726191
19
Efavirenz Approved, Investigational Phase 3,Phase 2 154598-52-4 64139
20
Lactitol Investigational Phase 3 585-86-4 3871
21 HIV Integrase Inhibitors Phase 3,Phase 2
22 Integrase Inhibitors Phase 3,Phase 2
23 Raltegravir Potassium Phase 3,Phase 2
24 Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 3
25 Dideoxynucleosides Phase 3
26 Antimetabolites Phase 3,Phase 1,Not Applicable
27 Cathartics Phase 3
28 Laxatives Phase 3
29 Vaccines Phase 3
30 Gastrointestinal Agents Phase 3
31 Immunologic Factors Phase 3
32
Etravirine Approved Phase 2 269055-15-4 193962
33 Cytochrome P-450 CYP2C19 Inhibitors Phase 2
34 Cytochrome P-450 CYP3A Inducers Phase 2
35 Cytochrome P-450 CYP2C9 Inhibitors Phase 2
36
Aldesleukin Approved Phase 1 85898-30-2, 110942-02-4
37
Zidovudine Approved Phase 1,Not Applicable 30516-87-1 35370
38 Interleukin-2 Phase 1
39 Analgesics, Non-Narcotic Phase 1
40 Peripheral Nervous System Agents Phase 1
41 Analgesics Phase 1
42 Dextrans Phase 1
43 Plasma Substitutes Phase 1
44 Anticoagulants Phase 1
45 Blood Substitutes Phase 1

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects Completed NCT02770508 Phase 4 darunavir/ritonavir;Lamivudine;emtricitabine-tenofovir(FTC/TDF)
2 Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects Completed NCT01449929 Phase 3 dolutegravir 50 mg OAD;darunavir 800mg OAD;ritonavir 100mg OAD
3 Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir Completed NCT01568892 Phase 3 Dolutegravir 50 mg twice daily;Dolutegravir placebo twice daily
4 A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. Completed NCT01328041 Phase 3 dolutegravir
5 A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects Completed NCT01499199 Phase 3 Dolutegravir
6 A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) Completed NCT01263015 Phase 3 Dolutegravir;Atripla;Abacavir/Lamivudine;Abacavir/Lamivudine Placebo;Dolutegravir placebo;Atripla placebo
7 A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Completed NCT01227824 Phase 3 GSK1349572 (dolutegravir);raltegravir
8 Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children Completed NCT01148459 Phase 3
9 A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults Active, not recruiting NCT01231516 Phase 3 GSK1349572;Raltegravir;GSK1349572 Placebo;Raltegravir Placebo
10 Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects Terminated NCT00197145 Phase 3 GW873140
11 A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir Completed NCT00950859 Phase 2 GSK1349572 (Cohort I);GSK1349572 (Cohort II)
12 A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Completed NCT00951015 Phase 2 GSK1349572;efavirenz
13 Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection Terminated NCT01199731 Phase 2 GSK2248761 100 mg once daily;GSK2248761 200 mg once daily;Etravirine
14 Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy Completed NCT00000728 Phase 1 Zidovudine;Aldesleukin
15 A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes Completed NCT00001012 Phase 1 AL 721
16 A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC) Completed NCT00001009 Phase 1 Dextran sulfate
17 The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) Completed NCT00002048 Not Applicable Zidovudine

Search NIH Clinical Center for Persistent Generalized Lymphadenopathy

Genetic Tests for Persistent Generalized Lymphadenopathy

Anatomical Context for Persistent Generalized Lymphadenopathy

MalaCards organs/tissues related to Persistent Generalized Lymphadenopathy:

41
Lymph Node, Skin, T Cells, B Cells, Monocytes, Ovary

Publications for Persistent Generalized Lymphadenopathy

Articles related to Persistent Generalized Lymphadenopathy:

(show top 50) (show all 57)
# Title Authors Year
1
Persistent generalized lymphadenopathy (PGL) mimicking lymphoma on whole-body FDG PET/CT imaging. ( 16785807 )
2006
2
Persistent generalized lymphadenopathy and non-Hodgkin's lymphoma in AIDS: association with Rochalimaea henselae infection. ( 7496912 )
1994
3
Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome. ( 1311993 )
1992
4
An open-label, dose-ranging trial of AL 721 in patients with persistent generalized lymphadenopathy and AIDS-related complex. ( 1890604 )
1991
5
Clinical manifestations of HIV infection, including persistent generalized lymphadenopathy and AIDS-related complex. ( 2193949 )
1990
6
Lymph nodes in HIV-positive drug abusers with persistent generalized lymphadenopathy: histology, immunohistochemistry, and pathogenetic correlations. ( 2103864 )
1990
7
Immunohistopathogenesis of persistent generalized lymphadenopathy in HIV-positive patients. ( 2192430 )
1990
8
Persistent generalized lymphadenopathy (transfusion-related) in an HIV-seropositive heterosexual man with sickle-cell beta-thalassemia. ( 2209816 )
1990
9
Persistent generalized lymphadenopathy syndrome vs "AIDS"--unrelated malignant lymphoma: comparison of presenting clinical and laboratory findings in 88 patients. AIDS and Related Syndromes Study Group. ( 2773074 )
1989
10
Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. ( 2491247 )
1989
11
The value of lymph node histology in human immunodeficiency virus related persistent generalized lymphadenopathy. ( 2736139 )
1989
12
Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) antigens and genome in lymph nodes of HIV-positive patients affected by persistent generalized lymphadenopathy (PGL). ( 2556016 )
1989
13
Paracortical immunoregulatory subpopulations in lymph nodes from homosexual men with persistent generalized lymphadenopathy. ( 3284806 )
1988
14
Clinical and laboratory findings at presentation in persistent generalized lymphadenopathy vs malignant lymphoma. ( 3180127 )
1988
15
Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy. ( 2902865 )
1988
16
Elevated serum beta-2-microglobulin--a prognostic marker for development of AIDS among patients with persistent generalized lymphadenopathy. ( 3286507 )
1988
17
Abnormal antibody responses in patients with persistent generalized lymphadenopathy. ( 2966810 )
1988
18
The pre-AIDS syndromes. Asymptomatic carriers, thrombocytopenic purpura, persistent generalized lymphadenopathy, and AIDS-related complex. ( 3060521 )
1988
19
Comparison of presenting clinical and laboratory findings of patients with persistent generalized lymphadenopathy (PGL) syndrome and malignant lymphoma (ML). ( 3126117 )
1987
20
B-cell reactivity in homosexuals with persistent generalized lymphadenopathy (PGL). ( 3500784 )
1987
21
Progressive histopathologic abnormalities in the persistent generalized lymphadenopathy syndrome. ( 3618883 )
1987
22
Subpopulations of CD4+ (T4+) cells in homosexual/bisexual men with persistent generalized lymphadenopathy. ( 2958183 )
1987
23
Flow cytometric lymphocyte immunophenotyping in homosexual men with the persistent generalized lymphadenopathy syndrome: a longitudinal study of lymph nodes and blood. ( 2962781 )
1987
24
Monoclonal antibodies to human immunodeficiency virus: their relation to the patterns of lymph node changes in persistent generalized lymphadenopathy and AIDS. ( 3130085 )
1987
25
Immunohistology of persistent generalized lymphadenopathy. Evidence for progressive lymph node abnormalities in some patients. ( 3300263 )
1987
26
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. ( 3301099 )
1987
27
Characterization of immunologic function in homosexual men with persistent, generalized lymphadenopathy and acquired immune deficiency syndrome. ( 3492262 )
1987
28
HLA-A, B and DR antigen frequencies in patients with AIDS-related persistent generalized lymphadenopathy (PGL) and thrombocytopenia. ( 3495904 )
1987
29
Impaired anti-pneumococcal antibody response in patients with AIDS-related persistent generalized lymphadenopathy. ( 3652522 )
1987
30
Damage to secondary lymphoid follicles in AIDS-related persistent generalized lymphadenopathy, as revealed by the behaviour of dendritic reticulum cells possessing immunoreactive acid cysteine-proteinase inhibitor. ( 2870581 )
1986
31
Increase of OKT4+ cells during treatment with thymostimulin in parenteral drug addicts with persistent generalized lymphadenopathy. ( 2942692 )
1986
32
Surgical biopsy for persistent generalized lymphadenopathy. ( 3004631 )
1986
33
HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. ( 3008562 )
1986
34
Early warning skin signs in AIDS and persistent generalized lymphadenopathy. ( 3008802 )
1986
35
Serum beta-2 microglobulin levels in homosexual men with AIDS and with persistent, generalized lymphadenopathy. ( 3008977 )
1986
36
Altered functions of peripheral blood monocytes in homosexual males and intravenous drug users with persistent generalized lymphadenopathy. ( 3015636 )
1986
37
Immunologic studies in homosexual and hemophiliac subjects with persistent generalized lymphadenopathy: a comparative analysis. ( 3484760 )
1986
38
Persistent generalized lymphadenopathy in Northeastern Italy: increased frequency of HLA-DR 5. ( 3486498 )
1986
39
Lymphangiography and abdominal computerized tomography in persistent generalized lymphadenopathy. ( 3487330 )
1986
40
Persistent generalized lymphadenopathy: clinical characteristics of a lymphadenopathy syndrome in intravenous drug abusers. ( 3489471 )
1986
41
The immunohistology of the persistent generalized lymphadenopathy syndrome (PGL). ( 3491535 )
1986
42
Persistent generalized lymphadenopathy in drug addicts: immunological studies. ( 3539149 )
1986
43
A histopathologic study of persistent generalized lymphadenopathy in intravenous drug abusers. ( 3737476 )
1986
44
Lymph node immunohistology in intravenous drug abusers with persistent generalized lymphadenopathy. ( 2996460 )
1985
45
Evaluation of natural killer cell activity in patients with persistent generalized lymphadenopathy and acquired immunodeficiency syndrome. ( 3874030 )
1985
46
The Vancouver Lymphadenopathy-AIDS Study: 1. Persistent generalized lymphadenopathy. ( 3995447 )
1985
47
Morphology of follicular centers in persistent generalized lymphadenopathy. ( 4025237 )
1985
48
Persistent generalized lymphadenopathy: immunological and mycological investigations. ( 2420116 )
1985
49
Epstein-Barr virus infections in homosexual men with chronic, persistent generalized lymphadenopathy. ( 2982964 )
1985
50
The syndrome of persistent generalized lymphadenopathy: experience with 101 patients. ( 2994423 )
1985

Variations for Persistent Generalized Lymphadenopathy

Expression for Persistent Generalized Lymphadenopathy

Search GEO for disease gene expression data for Persistent Generalized Lymphadenopathy.

Pathways for Persistent Generalized Lymphadenopathy

GO Terms for Persistent Generalized Lymphadenopathy

Cellular components related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.65 SDHA SDHAF2 SDHB SDHC SDHD
2 mitochondrial inner membrane GO:0005743 9.46 SDHA SDHB SDHC SDHD
3 respiratory chain complex II GO:0045273 8.96 SDHB SDHC
4 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.92 SDHA SDHB SDHC SDHD

Biological processes related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.73 SDHA SDHB SDHC SDHD
2 aerobic respiration GO:0009060 9.4 SDHB SDHC
3 B cell proliferation GO:0042100 9.37 CD40LG CD79A
4 tricarboxylic acid cycle GO:0006099 9.35 SDHA SDHAF2 SDHB SDHC SDHD
5 electron transport chain GO:0022900 9.33 SDHA SDHB SDHC
6 respiratory electron transport chain GO:0022904 9.32 SDHA SDHB
7 succinate metabolic process GO:0006105 9.26 SDHA SDHB
8 mitochondrial electron transport, succinate to ubiquinone GO:0006121 8.92 SDHA SDHAF2 SDHC SDHD

Molecular functions related to Persistent Generalized Lymphadenopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 electron transfer activity GO:0009055 9.46 SDHA SDHB SDHC SDHD
2 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.32 SDHA SDHC
3 succinate dehydrogenase activity GO:0000104 9.26 SDHA SDHD
4 ubiquinone binding GO:0048039 9.13 SDHB SDHC SDHD
5 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.92 SDHA SDHB SDHC SDHD

Sources for Persistent Generalized Lymphadenopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....